Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, oral melatonin given to male Pomeranian dogs with Alopecia X improved semen quality and testicular blood flow in a dose-dependent manner, but altered hormonal balance, indicating complex effects that require further investigation for long-term implications.

This retrospective study in a tertiary hair clinic concluded that routine monitoring of heart rate, weight, liver, and kidney function is not necessary for asymptomatic patients with normal baseline values undergoing low-dose oral minoxidil treatment, although monitoring is advised for those with preexisting renal impairment.

This study concluded that oral tofacitinib significantly improved hair growth in patients with alopecia areata, alopecia totalis, and alopecia universalis over a 24-week period, but longer studies are needed to assess long-term safety.

Low-dose oral minoxidil doesn't affect blood pressure in patients taking blood pressure meds.

This study reviewed adverse events associated with low-dose oral minoxidil for treating alopecia, finding hypertrichosis and fluid retention as common, typically manageable side effects without needing treatment discontinuation.

This study found that low-dose oral minoxidil effectively increased hair count over 24 weeks with mild reductions in blood pressure and minimal adverse effects among participants, suggesting its potential as a safe treatment for hair loss.

In this randomized trial, oral supplementation with Serenoa repens, pumpkin seed extracts, and cysteine significantly improved the clinical effectiveness of topical 5% minoxidil lotion for treating androgenic alopecia in men and women compared to minoxidil alone, with both treatments being well tolerated.

Combining PRP with topical minoxidil is most effective for hair growth in androgenetic alopecia.

Spironolactone helps prevent swelling caused by minoxidil in women with hair loss.

In this study, therapy successfully resolved mite infections in a domestic cat, leading to improved skin and ear health, including reduced crusting and itchiness, and cleaner ears after 15 days.

Low-dose oral minoxidil alone is effective for treating hair loss, but combining it with dutasteride or finasteride may offer better results.

This study found that initiating low-dose oral minoxidil did not significantly change alcohol consumption among 21,971 patients, suggesting a minimal impact on alcohol-related hangover symptoms.

This letter to the editor discusses blood pressure changes in patients taking low-dose oral minoxidil but reports no new research findings.

This research observed that in a prospective case series of 11 women with androgenetic alopecia, oral spironolactone improved hair thinning in most patients over 6 to 36 months, with mild side effects reported. However, effectiveness may be limited in advanced cases.

This source reports that an international panel of dermatologists has provided a consensus statement to guide clinicians on the off-label use of low-dose oral minoxidil for treating hair loss.

In this study of patients with androgenetic alopecia taking off-label low-dose oral minoxidil, adverse events like dizziness/lightheadedness, hypertrichosis, and extremity edema were observed in 14.9% of patients, with females experiencing more adverse events; higher doses increased dizziness risk, leading researchers to recommend cautious dosing approaches.

This case report describes an 18-month-old boy who developed a rare phototoxic skin reaction to terbinafine, likely triggered by sunlight exposure, which resolved after treatment with corticosteroid cream and sun avoidance.

In this retrospective study, tofacitinib showed promise as a treatment for alopecia areata, with 46.5% of patients experiencing a very good response and minimal adverse effects, suggesting it could be a primary option for moderate to severe cases.

This study examined the FDA Adverse Event Reporting System database and found significant associations between low-dose oral minoxidil use and adverse events like pericardial effusion, highlighting the need for caution and recommending the use of the lowest effective dose until more safety data are available.

In this case study, a 62-year-old woman with severe hyperandrogenism underwent a clomiphene test, which suggested an ovarian origin for her condition, leading to the discovery of a Leydig cell tumor after a bilateral oophorectomy.

Both treatment combinations improved hair growth similarly and were safe.

This study addresses the scarcity of information on the effectiveness and safety of low-dose oral minoxidil for treating COVID-19-associated telogen effluvium, a type of hair loss observed in some patients after COVID-19 infection, but does not report specific results.

In this study, low-dose oral minoxidil was found to be an effective and safe treatment for androgenetic alopecia, showing comparable outcomes in patients with AGA alone and those with AGA unmasked by telogen effluvium.

In this study, researchers found that low-dose oral minoxidil for androgenetic alopecia in men generally showed a good safety profile, with hypertrichosis being the most frequent side effect, while systemic side effects like dizziness and hypotension were less common and no life-threatening effects were observed.

This study found that a food supplement improved skin moisturization, elasticity, and thickness, reduced telogen hair density, and enhanced nail status in women with mild-to-moderate aging signs after 84 days.

Low-dose minoxidil helps hair grow longer and thicker in people with short anagen syndrome.

In this study, a survey of 84 Saudi Arabian dermatologists found increasing use of low-dose oral Minoxidil for hair loss management, though the limited sample size and English questionnaire may affect how well the findings represent the entire dermatologist population in the country.